Clinical cancer immunotherapy: Current progress and prospects

Chenglong Liu; Mengxuan Yang; Daizhou Zhang; Ming Chen; Di Zhu

doi:10.3389/fimmu.2022.961805

Clinical cancer immunotherapy: Current progress and prospects

Front Immunol. 2022 Oct 11:13:961805. doi: 10.3389/fimmu.2022.961805. eCollection 2022.

Authors

Chenglong Liu¹, Mengxuan Yang¹, Daizhou Zhang², Ming Chen^{3

4}, Di Zhu^{1

2

5}

Affiliations

¹ Minhang Hospital and Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
² New Drug Evaluation Center, Shandong Academy of Pharmaceutical Science, Jinan, China.
³ Department of Laboratory Medicine, Sixth Affiliated Hospital of Yangzhou University, Yangzhou, China.
⁴ Department of Laboratory Medicine, Affiliated Taixing Hospital of Bengbu Medical College, Taizhou, China.
⁵ Shanghai Engineering Research Center of ImmunoTherapeutics, Fudan University, Shanghai, China.

Abstract

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and robust therapeutic potential in clinical practice. It can significantly improve progression-free survival and overall survival. Following surgery, radiotherapy, chemotherapy, and targeted therapy, cancer treatment has now entered the age of immunotherapy. Although cancer immunotherapy has shown remarkable efficacy, it also suffers from limitations such as irAEs, cytokine storm, low response rate, etc. In this review, we discuss the basic classification, research progress, and limitations of cancer immunotherapy. Besides, by combining cancer immunotherapy resistance mechanism with analysis of combination therapy, we give our insights into the development of new anticancer immunotherapy strategies.

Keywords: CAR-T; cancer vaccines; immune checkpoint inhibitors; immunotherapy; tumor microenvironment.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Combined Modality Therapy
Immunologic Factors
Immunotherapy*
Neoplasms* / therapy

Substances

Immunologic Factors